Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 19/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228182 | 0.99 | PGR (0.74) | PGRNR3C1NR3C2ARPDE4A | |
| SCHEMBL3520566 | 0.88 | PGR (0.67) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4101396 | 0.86 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL4098486 | 0.84 | PGR (0.73) | PGRNR3C1NR3C2AR | |
| SCHEMBL4098488 | 0.84 | PGR (0.73) | PGRNR3C1NR3C2AR | |
| SCHEMBL3423569 | 0.84 | PGR (0.72) | PGRNR3C1NR3C2AR | |
| SCHEMBL3423573 | 0.84 | PGR (0.72) | PGRNR3C1NR3C2AR | |
| SCHEMBL3526645 | 0.82 | PGR (1.00) | PGRNR3C1NR3C2ARPDE4A | |
| SCHEMBL5226807 | 0.81 | PGR (0.75) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3870266 | 0.81 | PGR (0.67) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | claimed |
| US-6946454-B2 | Thio-oxindole derivatives | WYETH (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-20020169198-A1 | Thio-oxindole derivatives | WYETH (US) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169198-A1 | Thio-oxindole derivatives | GPER1, PGR, ESR1 | PGR 2/4885NR3C1 14/4885NR3C2 8/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | PGR 5/4885NR3C1 178/4885NR3C2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.